Atara Biotherapeutics (ATRA) Other Non-Current Liabilities (2013 - 2026)

Atara Biotherapeutics (ATRA) has 12 years of Other Non-Current Liabilities data on file, last reported at $1.8 million in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 41.51% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 41.51% YoY) and the FY2025 annual result came in at $1.8 million, down 45.09% from the prior year.
• Other Non-Current Liabilities grew to $1.8 million in Q1 2026, from $1.8 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $40.8 million in Q2 2025 to a low of $616000.0 in Q1 2022.
• A 5-year average of $6.0 million and a median of $4.4 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 69.6% — and 2025, when it surged 878.95%.
• Tracing ATRA's Other Non-Current Liabilities over 5 years: stood at $5.6 million in 2022, then decreased by 16.77% to $4.6 million in 2023, then retreated by 29.41% to $3.3 million in 2024, then slumped by 45.09% to $1.8 million in 2025, then advanced by 1.89% to $1.8 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $1.8 million (Q1 2026), $1.8 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.